STORAGE & DOSING

What you should know about the storage and dosing of SHINGRIX before vaccinating your patients.

Icon: 2 Vials

SHINGRIX is supplied as 2 vials for reconstitution:

  • 1 vial of antigen (powder) should be reconstituted with 1 accompanying vial of adjuvant suspension (liquid)
Watch How
Icon: Thermometer

Store refrigerated. DO NOT FREEZE:

  • Before reconstitution: Refrigerate both vials between 2°C and 8°C (36°F to 46°F). Protect vials from light. Discard if frozen
  • After reconstitution: Administer immediately or store refrigerated between 2°C and 8°C (36°F to 46°F) for up to 6 hours. Do not freeze; discard if frozen. Discard if not used within 6 hours
Icon: 2-Dose Series

SHINGRIX is given as a 2-dose series:

  • The first dose is administered at Month 0 followed by a second dose 2 to 6 months later
  • For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a shorter vaccination schedule, administer a first dose at Month 0 followed by a second dose 1 to 2 months later

Dosing schedule

The first dose is administered at Month 0 followed by a second dose 2 to 6 months later.
Dosing Schedule for SHINGRIX infographic

 1

Alternative dosing schedule

For those who are or will be immunodeficient or immunosuppressed and would benefit from a shorter vaccination schedule: administer a first dose at Month 0 followed by a second dose 1 to 2 months later.
Alternative dosing Schedule for SHINGRIX infographic

                     

Prescribing SHINGRIX

When referring patients to a pharmacy, e-prescribe SHINGRIX.

See how you can make the most of your EHR system

You may also be interested in:

Reconstitution & Administration

See how you and your staff can reconstitute SHINGRIX in 4 steps.

DISCOVER RECONSTITUTION

CDC Recommendations

See what CDC says about SHINGRIX. 

LEARN MORE

Safety Profile

Learn about the safety profile of SHINGRIX in immunocompromised patients aged 18 years and older.

SAFETY INFO

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or
1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Prescribing Information for SHINGRIX.

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET